January 20, 2023 07:31 AM EST

Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift'

Amber Tong

Kyle LaHucik

Senior Reporter

Atomwise, a well-connected player in the burgeoning space of artificial intelligence-powered drug discovery, cut its headcount by 30% in December, Endpoints News has learned. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift'

Amber Tong

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

Scoop: Just months af­ter Sanofi AI deal, Atom­wise laid off 30% of staffers amid 's­trate­gic shift'

Senior Reporter

Sign up to read this article for free.

Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift'